Fracture risk assessment in clinical practice: T-scores, FRAX, and beyond

被引：3
作者：
Lewiecki E.M. [1 ]
机构：
[1] New Mexico Clinical Research and Osteoporosis Center, Albuquerque, NM 87106
来源：
Clinical Reviews in Bone and Mineral Metabolism | 2010年 / 8卷 / 3期
关键词：
BMD; Bone mineral density; Clinical risk factors; FRAX; Osteoporosis; Prevention; T-score; Treatment;
D O I：
10.1007/s12018-009-9054-6
中图分类号：
学科分类号：
摘要：
Assessment of fracture risk is a key component in the evaluation of skeletal health and a critical step in determining whether to initiate pharmacological therapy to reduce fracture risk. The identification of high risk patients allows clinicians to direct limited healthcare resources to those who are most likely to benefit. Bone mineral density (BMD) and clinical risk factors (CRFs) for fracture predict fracture risk better than BMD or CRFs alone. Dual-energy X-ray absorptiometry (DXA) is a technology for the measurement of BMD to diagnose osteoporosis, assess fracture risk, and monitor the BMD response to therapy. Validated CRFs and femoral neck BMD by DXA, when available, provide the input for the World Health Organization fracture risk assessment tool (FRAX) to estimate the 10-year probability of fracture in untreated patients. Economic models have included FRAX in calculations to estimate when pharmacological intervention is likely to be cost-effective in reducing fracture risk. Cost-effectiveness is one of many factors to consider in making treatment decisions. This is a review of the benefits and limitations of BMD testing, CRFs, and FRAX in the management of patients in clinical practice. © 2009 Humana Press Inc.
引用
收藏
页码：101 / 112
页数：11
相关论文
共 107 条
  • [11] Kanis J.A., Johnell O., Requirements for DXA for the management of osteoporosis in Europe, Osteoporos Int, 16, 3, pp. 229-238, (2005)
  • [12] Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis, (1994)
  • [13] Baim S., Binkley N., Bilezikian J.P., Kendler D.L., Hans D.B., Lewiecki E.M., Et al., Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference, J Clin Densitom, 11, 1, pp. 75-91, (2008)
  • [14] FRAX WHO Fracture Risk Assessment Tool
  • [15] McCloskey E.V., Johansson H., Oden A., Vasireddy S., Kayan K., Pande K., Et al., Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study, Osteoporos Int, 20, 5, pp. 811-817, (2009)
  • [16] Kanis J.A., Johansson H., Oden A., McCloskey E.V., Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX((R)), Bone, 44, 6, pp. 1049-1054, (2009)
  • [17] Liberman U.A., Weiss S.R., Broll J., Minne H., Quan H., Bell N.H., Et al., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis, N Engl J Med, 333, pp. 1437-1443, (1995)
  • [18] Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Et al., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, pp. 1535-1541, (1996)
  • [19] Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., Et al., Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures-results from the fracture intervention trial, JAMA, 280, 24, pp. 2077-2082, (1998)
  • [20] McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., Et al., Effect of risedronate on the risk of hip fracture in elderly women, N Engl J Med, 344, pp. 333-340, (2001)
12345678910